Clearside Biomedical (CLSD) is Initiated by Stifel to Buy, Price Target at $13

Clearside Biomedical (CLSD) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $13. Stifel advised their investors in a research report released on Jun 27, 2016.

Many Wall Street Analysts have commented on Clearside Biomedical. Wedbush Initiated Clearside Biomedical on Jun 27, 2016 to “Outperform”, Price Target of the shares are set at $28.

Clearside Biomedical

Leave a Reply

Clearside Biomedical - Is it time to Sell?

Top Brokerage Firms are advising their investors on Clearside Biomedical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.